[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"induction-therapy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:induction-therapy":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,49,81,105,129],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100468872","phase-3-induction-in-sensitized-kidney-transplant-recipients-without-pre-existing-donor-specific-antibodies-100468872",false,"NCT05385432","Induction in Sensitized Kidney Transplant Recipients Without Pre-existing Donor-specific antiboDies","Induction in Sensitized Kidney Transplant Recipients Without Preexisting Donor-specific antiboDies: a Randomized Multicentre Trial Between a Lymphocyte Depleting and Basiliximab.","INSTEAD","Inclusion Criteria:\n\n* Patients aged between 18-79\n* Registered on the transplant waiting list\n* At least one anti-HLA antibody identified by the Luminex Single Antigen test with MFI ≥ 2000 (MFI threshold in agreement with French kidney allocation system.)\n* Graft incompatibility rate (TGI) \\\u003C 85%\n* Ability for participant to comply with the requirements of the study\n* Written informed consent obtained from the participant\n* Participants covered by or entitled to social security.\n\nExclusion Criteria:\n\n* DSA (negative virtual crossmatch with MFI threshold at 1000)\n* Combined transplantation\n* Usual contraindications to a kidney transplantation such as morbid obesity (BMI \\> 40 kg\u002Fm2), active drug abuse, uncontrolled psychiatric disease, or decompensated heart failure\n* Beneficiaries of kidney transplants from donations after uncontrolled circulatory death (Maastricht II)\n* Incompatible ABO transplantation\n* Leukopenia lower than 3000\u002Fmm3\n* Thrombocytopenia (platelets \\\u003C 50G\u002FL)\n* Donor EBV Positive \u002F Recipient EBV Negative\n* Active HIV infection (positive viral charge)\n* History of solid cancer (\\\u003C 5 years), except to skin carcinoma (squamous-cell and basal-cell carcinoma).History of some solid cancer (prostate, breast) can be reduced (\\\u003C2 years), depending on the prognosis for cancer recurrence as assessed by the oncologist.\n* History of lymphoma\n* Patients with severe uncontrolled systemic infection or severe allergy requiring acute or chronic treatment; Aspartate aminotransferase (ASAT), Alanine Amino Transferase (ALAT) or bilirubin greater than 3 times normal\n* Known hypersensitivity or contra-indication to rabbit proteins, basiliximab including the product excipients\n* Contra-indication to tacrolimus,mycophenolic acid ans steroids\n* Pregnant or breastfeeding woman, or woman of childbearing potential not using a highly effective method of contraception, or having a desire to conceive, during the whole trial duration. A β-HCG test will be performed for inclusion.\n* Patient under judicial protection, deprivation of liberty\n* Participation in other interventional research with an investigational drug or medical device.","ALL","18 Years","79 Years",{"count":21,"type":22},244,"ESTIMATED","INTERVENTIONAL",[25],"PHASE3","Induction therapy decreases the rate of acute allograft rejection in kidney transplant recipients (KTRs) and is strongly recommended. Polyclonal lymphocyte-depleting antibodies and interleukin-2 receptor (IL2R) antagonists are therefore widely used around the world, with a leading position for rabbit anti-thymocyte globulin (rATG, Thymoglobulin®) and basiliximab (Simulect®), respectively. The actual immunological risk of the sensitized KTRs without donor specific antibodies (DSAs) is still debated. The benefit-risk equation of lymphocyte depleting antibodies (versus IL2R antagonists) is not known in sensitized KTRs without DSAs. This clinical trial will compare the efficacy and safety of basiliximab and rATG in sensitized KTR without pre-existing DSAs detected by Luminex.",[28,29],"Renal Transplant Rejection","Induction Therapy",[31,32,33,34,35],"Kidney transplantation","Basiliximab","ATG","induction","rejection","RECRUITING","2026-06-16",{"date":39,"type":40},"2026-06-18","ACTUAL",{"date":42,"type":40},"2023-11-07",{"date":44,"type":22},"2030-12-30",{"name":46,"class":47},"University Hospital, Tours","OTHER",1,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":4,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":56,"enrollmentInfo":57,"targetDuration":4,"studyType":23,"phases":59,"briefSummary":61,"conditions":62,"keywords":66,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":48},"100599962","phase-2-a-study-of-ql1706-combined-with-chemotherapy-induction-on-sequential-immunotherapy-consolidation-in-patients-with-limited-stage-small-cell-lung-cancer-after-chemoradiotherapy-100599962","NCT07091305","A Study of QL1706 Combined With Chemotherapy Induction on Sequential Immunotherapy Consolidation in Patients With Limited-Stage Small Cell Lung Cancer After Chemoradiotherapy","A Study of QL1706 Combined With Chemotherapy Induction on Sequential Immunotherapy Consolidation in Patients With Limited-Stage Small Cell Lung Cancer After Chemoradiotherapy：A Phase II Trial","Inclusion Criteria:\n\n1. The patient must be aged between 18 and 75 years (inclusive of boundary values), and both males and females are eligible.\n2. Pathologically confirmed LS-SCLC\n3. Investigator confirmation of at least one measurable lesion, as defined by RECIST v1.1\n4. ECOG performance status of 0 or 1\n5. Forced expiratory volume in one second (FEV₁) \\> 1.0 L\n6. No clinically significant interstitial lung disease on baseline CT or PET\u002FCT.\n7. Adequate organ and bone-marrow function (all tests performed within 7 days prior to first dose; no transfusions, growth factors, albumin, or other corrective therapies within 14 days):Hemoglobin ≥ 90 g\u002FL, ANC ≥ 1.5 × 10⁹\u002FL, PLT ≥ 90 × 10⁹\u002FL,Serum creatinine ≤ 1.5 × ULN, TBIL ≤ 1.5 × ULN, ALT and AST ≤ 3 × ULN, Albumin (ALB) ≥ 25 g\u002FL,INR ≤ 1.5 × ULN, PT and APTT ≤ 1.5 × ULN (subjects on prophylactic anticoagulation must have values within a safe therapeutic range, per investigator)\n8. Women of childbearing potential must have a negative serum or urine pregnancy test within 7 days prior to enrollment and agree to use reliable contraception from screening until 3 months after the last dose; male subjects must agree to use effective contraception or have undergone surgical sterilization for the same period.\n9. No prior systemic anti-tumor therapy before enrollment.\n10. Estimated life expectancy ≥ 12 weeks.\n\nExclusion Criteria:\n\n1. Known hypersensitivity to QL1706 or any of its excipients\n2. Histologically confirmed non-small cell lung cancer (NSCLC) or mixed tumor containing an NSCLC component.\n3. History of another primary malignancy or previous allogeneic organ transplantation.\n4. Surgery (other than diagnostic biopsy) within 4 weeks before first dose of study drug.\n5. Active substance abuse (e.g., illicit drug use), chronic alcoholism, AIDS, or known HIV infection.\n6. Active autoimmune disease, or history of autoimmune disease likely to recur. Systemic corticosteroid therapy equivalent to \\>10 mg\u002Fday prednisone (or other immunosuppressive therapies) within 14 days before first dose.\n7. Prior therapy with any antibody or agent targeting T-cell co-regulatory proteins (e.g., PD-1, PD-L1, CTLA-4, TIM-3, LAG-3).\n8. Interstitial lung disease (ILD), or history of ILD requiring steroid therapy. History of idiopathic pulmonary fibrosis, drug-induced pneumonitis, organizing pneumonia (e.g., bronchiolitis obliterans), or evidence of active pneumonia on screening chest CT.\n9. Live vaccine administration within 28 days prior to first study drug dose. Any condition or comorbidity contraindicating chemo- or radiotherapy (e.g., active infection, myocardial infarction within 6 months, symptomatic heart disease including unstable angina, congestive heart failure, uncontrolled arrhythmia, ongoing immunosuppressive therapy).\n10. Pregnant or breastfeeding women; women of childbearing potential or men unwilling to use adequate contraception.\n11. Known hereditary bleeding diathesis or coagulation disorder.\n12. Prior malignancy, except adequately treated non-melanoma skin cancer, or in situ carcinoma (e.g., breast, oral, cervical) with expected survival \\>3 years.\n13. Any other medical, psychiatric, or laboratory abnormality that, in the investigator's judgment, could interfere with trial participation or interpretation of results.","75 Years",{"count":58,"type":22},28,[60],"PHASE2","The study is being conducted to evaluation of the Efficacy and Safety of QL1706 Combined with Chemotherapy Induction in Sequential Immunotherapy Consolidation After Concurrent Chemoradiotherapy for Limited-Stage Small Cell Lung Cancer(LS-SCLC), and Exploration of the Correlation Between Biomarkers (PD-L1, TMB, ctDNA, etc.) Related to QL1706 Treatment and Treatment Efficacy and Prognosis.\n\nQL1706 (Iparomlimab and Tuvonralimab) is a single bifunctional MabPair product against PD-1 and CTLA-4. QL1604 is a monoclonal antibody against PD-1.",[63,64,29,65],"Limited-stage Small Cell Lung Cancer (LS-SCLC)","Chemoradiotherapy","Consolidation Immunotherapy",[67,68,69,70,71],"Limited-stage small cell lung cancer","QL1706","chemoradiotherapy","induction therapy","consolidation immunotherapy","2026-06-10",{"date":74,"type":40},"2026-06-11",{"date":76,"type":40},"2025-10-23",{"date":78,"type":22},"2028-08-01",{"name":80,"class":47},"Shanghai Chest Hospital",{"id":82,"slug":83,"hasResults":11,"nctId":84,"briefTitle":85,"officialTitle":86,"acronym":4,"eligibilityCriteria":87,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":88,"enrollmentInfo":89,"targetDuration":4,"studyType":23,"phases":91,"briefSummary":92,"conditions":93,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":48},"100599495","phase-2-iparomlimabtuvorlimab-ql1706-and-modified-tpf-regimen-for-induction-therapy-in-lanpc-100599495","NCT07085234","Iparomlimab\u002FTuvorlimab (QL1706) and Modified TPF Regimen for Induction Therapy in LANPC","The Efficacy and Safety of Iparomlimab\u002FTuvorlimab (QL1706) Combined With Modified TPF Regimen for Induction Therapy in Locally Advanced Nasopharyngeal Carcinoma","Inclusion Criteria:\n\n* Age: ≥ 18 years old;\n* Patients with nasopharyngeal carcinoma diagnosed by pathology (including histology or cytology), with a clinical stage of III - IV (excluding T3N0 - 1) (according to the UICC\u002FAJCC TNM staging system (8th edition));\n* No prior systematic treatment (surgery, radiotherapy, chemotherapy, etc.); At least one measurable lesion on imaging examination (according to RECIST criteria version 1.1);\n* ECOG PS: 0 - 1 points;\n* Expected survival time ≥ 3 months;\n* Normal function of major organs, meeting the following criteria:\n\n  1. Blood routine tests should meet the following (without blood transfusion within 14 days):\n\n     1. HB ≥ 100 g\u002FL,\n     2. WBC ≥ 3 × 10⁹\u002FL,\n     3. ANC ≥ 1.5 × 10⁹\u002FL,\n     4. PLT ≥ 100 × 10⁹\u002FL;\n  2. Biochemical tests should meet the following criteria:\n\n     1. BIL \\\u003C 1.5 times the upper limit of normal (ULN),\n     2. ALT and AST \\\u003C 2.5 ULN, GPT ≤ 1.5 × ULN;\n     3. Serum Cr ≤ 1 ULN, endogenous creatinine clearance rate \\> 60 ml\u002Fmin (Cockcroft - Gault formula);\n* Male subjects and women of childbearing potential must use contraception from the start of the first dose of the study drug until 24 weeks after the last dose of the study drug;\n* Normal function of major organs, with basically normal blood routine, blood biochemistry and coagulation function tests;\n* The investigator believes that the patient will benefit from the treatment in terms of survival;\n* The patient voluntarily participates in this study and provides a written informed consent form.\n\nExclusion Criteria:\n\n* Active, known, or suspected autoimmune diseases;\n* Patients with hypertension whose blood pressure cannot be controlled within the normal range with antihypertensive medications (systolic blood pressure \\> 160 mmHg, diastolic blood pressure \\> 90 mmHg);\n* Inherited bleeding tendency or coagulation disorders. Clinically significant bleeding symptoms occurred within 12 weeks before screening or there is a definite bleeding tendency (cumulative blood loss exceeding 50 ml within 24 hours);\n* Uncontrolled cardiac clinical symptoms or diseases, such as: (1) Heart failure of NYHA class II or above; (2) Unstable angina; (3) Myocardial infarction within 24 weeks; (4) Clinically significant supraventricular or ventricular arrhythmias requiring treatment or intervention;\n* Interstitial lung disease, drug-induced pneumonia, radiation pneumonia requiring steroid treatment, active pneumonia with clinical symptoms, or severe pulmonary function impairment;\n* Subjects with active hepatitis B (HBV DNA ≥ 2000 IU\u002FmL or 10⁴ copies\u002FmL) or hepatitis C (positive for hepatitis C antibody and HCV-RNA above the lower limit of detection of the analytical method);\n* Subjects with allergic reactions to the drugs used in this study;\n* Pregnant or lactating women;\n* Other conditions considered by the investigator as unsuitable for participation in this study.","65 Years",{"count":90,"type":22},30,[60],"This is a prospective, open-label, multicenter, single-arm clinical study. A total of 30 patients with locally advanced nasopharyngeal carcinoma who have not received prior systemic treatment are planned to be enrolled at three centers. After enrollment, the patients will receive induction therapy with Iparomlimab\u002FTuvorlimab(QL-1706) in combination with a modified TPF regimen, followed by concurrent chemoradiotherapy with cisplatin according to the standards of clinical practice.",[94,95,29],"Locally Advanced Nasopharyngeal Carcinoma","Immunotherapy","2025-07-17",{"date":98,"type":40},"2025-07-25",{"date":100,"type":22},"2025-07-30",{"date":102,"type":22},"2029-12-31",{"name":104,"class":47},"The First Affiliated Hospital of Xiamen University",{"id":106,"slug":107,"hasResults":11,"nctId":108,"briefTitle":109,"officialTitle":110,"acronym":4,"eligibilityCriteria":111,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":88,"enrollmentInfo":112,"targetDuration":4,"studyType":23,"phases":114,"briefSummary":115,"conditions":116,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":122,"startDateStruct":124,"completionDateStruct":126,"leadSponsor":127,"locationsCount":128},"100578480","phase-2-two-cycle-and-three-cycle-induction-therapy-with-modified-tpf-regimen-combined-and-camrelizumab-for-lanpc-100578480","NCT06811844","Two-cycle and Three-cycle Induction Therapy With Modified TPF Regimen Combined and Camrelizumab for LANPC","Comparison of Two-cycle and Three-cycle Induction Therapy With Modified TPF Regimen Combined and Camrelizumab for Locally Advanced Nasopharyngeal Carcinoma: A Prospective, Phase II, Multicenter, Randomized Controlled Study","Inclusion Criteria:\n\n* Age: 18-65 years old;\n* Pathologically (including histology or cytology) confirmed nasopharyngeal carcinoma patients, with clinical staging T1-4N2-3M0 (according to the UICC\u002FAJCC TNM staging system, 8th edition);\n* No prior systemic treatment (surgery, radiotherapy, chemotherapy, etc.);\n* At least one measurable lesion on imaging (as per RECIST criteria version 1.1);\n* ECOG Performance Status (PS): 0-1;\n* Expected survival ≥3 months;\n* Male subjects and women of childbearing potential must use contraception from the first dose of study medication until 24 weeks after the last dose of study medication;\n* Normal major organ function, with basic normal results in hematology, biochemistry, and coagulation tests;\n* The investigator believes that the treatment will provide a survival benefit.\n\nExclusion Criteria:\n\n* Active, known, or suspected autoimmune disease;\n* Patients with hypertension that cannot be controlled to normal range despite antihypertensive medication (systolic BP \\>160 mmHg, diastolic BP \\>90 mmHg);\n* History of hereditary bleeding tendency or coagulation dysfunction. Any clinically significant bleeding symptoms within 12 weeks prior to screening, or cumulative bleeding over 50 ml in 24 hours;\n* Unwell-controlled cardiac clinical symptoms or diseases;\n* Interstitial lung disease, drug-induced pneumonia, steroid-treated radiation pneumonitis, active pneumonia with symptoms, or severe pulmonary dysfunction;\n* Active hepatitis B (HBV DNA ≥2000 IU\u002FmL or 10\\^4 copies\u002FmL), hepatitis C (HCV antibody positive and HCV-RNA above the lower limit of detection of the assay);\n* Allergy to any of the study drugs;\n* Pregnant or breastfeeding women;\n* Any other factors that, in the investigator's judgment, may cause premature termination of the study.",{"count":113,"type":22},208,[60],"This prospective, phase II, multicenter, randomized controlled study aims to compare the complete response rate and long-term survival outcomes of two-cycle and three-cycle induction therapy with modified TPF regimens combined with camrelizumab in patients with locally advanced nasopharyngeal carcinoma.",[117,118,29,119,120],"Nasopharyngeal Neoplasms","PD-1 Inhibitor","Complete Response","Chemotherapy","2025-06-30",{"date":123,"type":40},"2025-07-01",{"date":125,"type":40},"2025-02-25",{"date":102,"type":22},{"name":104,"class":47},3,{"id":130,"slug":131,"hasResults":11,"nctId":132,"briefTitle":133,"officialTitle":134,"acronym":4,"eligibilityCriteria":135,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":136,"enrollmentInfo":137,"targetDuration":4,"studyType":23,"phases":139,"briefSummary":140,"conditions":141,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":144,"lastUpdatePostDateStruct":145,"startDateStruct":147,"completionDateStruct":149,"leadSponsor":151,"locationsCount":128},"100548467","phase-2-induction-chemoimmunotherapy-combined-with-chemoradiotherapy-in-esophageal-cancer-100548467","NCT06421376","Induction Chemoimmunotherapy Combined With Chemoradiotherapy in Esophageal Cancer","Efficacy and Safety of Inductive Chemoimmunotherapy Followed by Chemoradiotherapy With or Without Surgery in Locally Advanced Esophageal Squamous Cell Cancer: a Single-arm, Prospective, Phase II Trial","Inclusion Criteria:\n\n* 18-80 years old；\n* Eligible patients were histologically confirmed esophageal squamous cell carcinoma;\n* Eligible patients were proven locally advanced ESCC (cT1-2N1-3M0-1, cT3\u002FT4N0-3M0-1, M1 was limited to supraclavicular lymph node metastasis）diagnosed by computed tomography \\[CT\\] and\u002For endoscopic ultrasonography \\[EUS\\] according to the American Joint Committee on Cancer (AJCC) 8th edition staging system；\n* ECOG PS score: 0\\~1；\n* Main organs and bone marrow function are normal: routine blood tests: hemoglobin (Hb) ≥100g\u002FL ; absolute neutrophil count (NEUT)≥1.5×109\u002FL; platelets (PLT) ≥100×109\u002FL; white blood cell (WBC)≥3.5×109\u002FL,biochemical examination: alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤1.5×UNL; serum total bilirubin (TBIL) ≤1.5×UNL; serum creatinine ( Cr) 1.0×1.5UNL, and BUN≤1.0×UNL;\n\nExclusion Criteria:\n\n* Those combined with other primary malignant tumors other than esophageal cancer (except cured basal cell carcinoma of the skin and carcinoma in situ of the cervix);\n* patients who had previously received other treatments\n* At the time of diagnosis, there were distant and hematogenous metastases beyond the supraclavicular lymph node region, including retroperitoneal multiple lymph node metastasis, bone metastasis, brain metastasis, lung metastasis, liver metastasis, malignant pleural effusion and ascites\n* Those who already have esophageal perforation or are at high risk of esophageal perforation\n* Patients whose tumors invade close to large blood vessels and are at risk of bleeding in the\n* there are active infections, such as active tuberculosis and hepatitis\n* There are contraindications to immunotherapy.\n* Pregnant or lactating women and women of childbearing age do not take reliable contraceptive measures\n* Combined with serious cardiovascular diseases, such as uncontrolled heart failure, coronary heart disease, cardiomyopathy, uncontrolled arrhythmia, uncontrolled hypertension, or a history of myocardial infarction within the past 6 months; and those combined with other uncontrolled acute and chronic diseases such as hypertension and diabetes.\n* Violation of inclusion and exclusion criteria, or other reasons that the researcher believes cannot continue the study of drug treatment.","80 Years",{"count":138,"type":22},60,[60],"Although unprecedented advances have been made in the field of esophageal cancer in recent decades, the prognosis for patients with locally advanced esophageal squamous cell carcinoma (ESCC) remains extremely poor, accounting for 30-40% of overall survival at 5 year. In recent years, multimodal treatments have proven to be an appropriate therapeutic approach for locally advanced ESCC. Recently, immunotherapy developed rapidly. The purpose of this study was to observe the efficacy and safety of cardonilizumab combined with chemoradiotherapy in the treatment of locally advanced ESCC.",[142,95,29,64,143],"Esophageal Cancer","Surgery","2025-05-24",{"date":146,"type":40},"2025-05-30",{"date":148,"type":40},"2024-05-01",{"date":150,"type":22},"2027-12-31",{"name":152,"class":47},"Cancer Institute and Hospital, Chinese Academy of Medical Sciences"]